Ronald Blue Co Lowers stake in Pfizer (PFE)

Pfizer (PFE) : Ronald Blue Co reduced its stake in Pfizer by 7.94% during the most recent quarter end. The investment management company now holds a total of 34,558 shares of Pfizer which is valued at $1,128,664 after selling 2,979 shares in Pfizer , the firm said in a disclosure report filed with the SEC on Oct 17, 2016.Pfizer makes up approximately 0.05% of Ronald Blue Co’s portfolio.

Other Hedge Funds, Including , Dorchester Wealth Management Co boosted its stake in PFE in the latest quarter, The investment management firm added 24,681 additional shares and now holds a total of 146,235 shares of Pfizer which is valued at $4,776,035. Pfizer makes up approx 1.80% of Dorchester Wealth Management Co’s portfolio.Carl Domino Inc reduced its stake in PFE by selling 4,016 shares or 7.34% in the most recent quarter. The Hedge Fund company now holds 50,715 shares of PFE which is valued at $1,680,188. Pfizer makes up approx 1.60% of Carl Domino Inc’s portfolio.First Financial Bank N.a. – Trust Division boosted its stake in PFE in the latest quarter, The investment management firm added 7,044 additional shares and now holds a total of 179,676 shares of Pfizer which is valued at $6,038,910. Pfizer makes up approx 1.12% of First Financial Bank N.a. – Trust Division’s portfolio.First American Trust Fsb boosted its stake in PFE in the latest quarter, The investment management firm added 1,331 additional shares and now holds a total of 189,440 shares of Pfizer which is valued at $6,422,016. Pfizer makes up approx 2.02% of First American Trust Fsb’s portfolio.

Pfizer closed down -0.1 points or -0.31% at $32.66 with 1,55,69,339 shares getting traded on Friday. Post opening the session at $32.73, the shares hit an intraday low of $32.66 and an intraday high of $32.9 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.

On the company’s financial health, Pfizer reported $0.64 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Aug 2, 2016. Analyst had a consensus of $0.62. The company had revenue of $13147.00 million for the quarter, compared to analysts expectations of $13013.24 million. The company’s revenue was up 10.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.56 EPS.

Investors should note that on Sep 22, 2016, Pfizer announced a cash dividend of $0.3000. The company’s management has announced Nov 9, 2016 as the ex-dividend date and fixed the record date on Nov 11, 2016. The payable date has been fixed on Dec 1, 2016.

Many Wall Street Analysts have commented on Pfizer. Pfizer was Downgraded by Jefferies to ” Hold” on Oct 13, 2016.

Pfizer Inc. is a global biopharmaceutical company. The Company is engaged in discovering developing and manufacturing of healthcare products. Its products include Lyrica the Prevnar family of products Enbrel Celebrex Lipitor Viagra Zyvox Sutent EpiPen Toviaz Tygacil Rapamune Xalkori Inlyta Norvasc BeneFIX Genotropin and Enbrel among others. It operates in three segments: Global Innovative Pharmaceutical segment (GIP) Global Vaccines Oncology and Consumer Healthcare segment (VOC) and Global Established Pharmaceutical segment (GEP). GIP is focused on developing registering and commercializing medications in therapeutic areas such as inflammation cardiovascular/metabolic neuroscience and pain rare diseases and women’s/men’s health. VOC focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. GEP includes its sterile injectable products and bio similar development portfolio. Its subsidiary is Hospira Inc.

Leave a Reply

Pfizer - Is it time to Sell?

Top Brokerage Firms are advising their investors on Pfizer. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.